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D

ecorin, a member of the small leucine-rich proteoglycan gene family, impedes tumor cell growth
by down-regulating the epidermal growth factor
receptor. Decorin has a complex binding repertoire, thus,
we predicted that decorin would modulate the bioactivity
of other tyrosine kinase receptors. We discovered that
decorin binds directly and with high affinity (Kd = 1.5 nM)
to Met, the receptor for hepatocyte growth factor (HGF).
Binding of decorin to Met is efficiently displaced by
HGF and less efficiently by internalin B, a bacterial Met

ligand. Interaction of decorin with Met induces transient
receptor activation, recruitment of the E3 ubiquitin ligase
c-Cbl, and rapid intracellular degradation of Met (halflife = 6 min). Decorin suppresses intracellular levels of
-catenin, a known downstream Met effector, and inhibits
Met-mediated cell migration and growth. Thus, by antagonistically targeting multiple tyrosine kinase receptors,
decorin contributes to reduction in primary tumor growth
and metastastic spreading.

Introduction
The extracellular matrix and its multiple constituents play both
a structural and signaling role by interacting with surface receptors that ultimately affect gene expression, cell phenotypes, development, and cancer (Ramirez and Rifkin, 2003; Weigelt and
Bissell, 2008). Decorin, a member of the small leucine-rich
proteoglycan gene family that harbors one chondroitin/dermatan
sulfate side chain at its N terminus, was originally named because of its ability to “decorate” collagen fibrils, thereby regulating fibrillogenesis, a key mechanism of matrix assembly and
homeostasis (Schaefer and Iozzo, 2008). It was soon discovered
that decorin regulates the TGF- signaling pathway and also inhibits the growth of a variety of tumor cells (Iozzo, 1998) by
down-regulating the EGF receptor (EGFR; Iozzo et al., 1999b)
and other members of the ErbB family of receptor tyrosine kinase (RTK; Goldoni and Iozzo, 2008). Decorin suppresses
tumor cell–mediated angiogenesis by inhibiting the endogenous
production of vascular endothelial cell growth factor (Grant
et al., 2002) similar to neutralizing antibodies directed toward
EGFR (Petit et al., 1997). Genetic deficiency of decorin causes

intestinal tumor formation through disruption of intestinal cell
maturation (Bi et al., 2008), whereas mice with a double deficiency
of decorin and p53 succumb prematurely to aggressive lymphomas (Iozzo et al., 1999b). Together, these observations indicate
that lack of decorin is permissive for in vivo tumorigenesis.
Ectopic expression of decorin induced by stable transgenic systems, viral vectors, or inducible promoters attenuates
the growth of tumor xenografts with diverse histogenetic origin
(Santra et al., 1995, 2000; Csordás et al., 2000; Reed et al.,
2002, 2005; Tralhão et al., 2003; Biglari et al., 2004; Seidler
et al., 2006). Decorin slows the growth of squamous cell and
breast carcinomas by inducing a sustained down-regulation of
the EGFR (Csordás et al., 2000) and ErbB2 (Santra et al., 2000),
a process that leads to a p21WAF1-mediated growth suppression
and enhanced cytodifferentiation of mammary carcinoma cells
(Santra et al., 2000). The basic mechanism has been partially
elucidated and includes direct binding to the EGFR followed by
protracted internalization of the receptor via caveolar-mediated
endocytosis (Zhu et al., 2005) and the triggering of apoptosis
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via caspase-3 activation (Seidler et al., 2006). Moreover, decorin inhibits myeloma cell growth (Li et al., 2008b), and systemic
delivery of decorin reduces pulmonary metastases in two animal
models (Goldoni et al., 2008; Shintani et al., 2008). Notably,
decorin-induced growth inhibition in osteosarcoma MG63 cells
is overcome by a constitutive activation of EGFR (Zafiropoulos
et al., 2008).
Because of the complex binding capabilities of decorin
toward multiple targets (Brandan et al., 2008; Schaefer and Iozzo,
2008) and its dramatic antioncogenic effects (Reed et al., 2002,
2005; Goldoni et al., 2008), we predicted a role for decorin in modulating the bioactivity of other RTK. We discovered that decorin binds directly to the Met receptor, also known as hepatocyte
growth factor (HGF) receptor, an established mediator of malignant transformation, invasion, and metastasis (DanilkovitchMiagkova and Zbar, 2002; Birchmeier et al., 2003; Knudsen
and Vande Woude, 2008). Our findings indicate that decorin is a
novel antagonistic ligand of the Met receptor. Apart from HGF,
decorin is the only mammalian ligand known to date. Interaction
between decorin and the extracellular domain of Met leads to
receptor down-regulation through a combination of enhanced
ectodomain shedding and internalization. Decorin-induced inhibition of Met activity results in suppression of key biological
events. Notably, decorin induces a marked proteasome-dependent
degradation of the transcription factor -catenin and inhibits
Met-dependent cell motility. Collectively, our findings point to
decorin as a novel inhibitor of the Met receptor. The ability of
decorin to antagonize multiple receptors, including Met, EGFR,
and ErbB2/ErbB4, suggests that this leucine-rich proteoglycan
might have therapeutic value in treatment of cancers in which
several RTKs are coactivated.

Results
Decorin down-regulates the Met receptor

To discover new pathways affected by decorin, we used an antibody array system that simultaneously examines the relative Tyr
phosphorylation level of 42 different RTKs. After a 15-min exposure of quiescent (serum starved) HeLa cells to 100 nM recombinant decorin, there was a rapid phosphorylation of the EGFR
(Fig. 1 A) in agreement with our previous experiments (Iozzo
et al., 1999b). In addition, a novel target was found in the Met receptor, which showed a decorin-evoked increase in phosphorylation
when the cells were quiescent (Fig. 1 A) and a marked suppression
when the cells were cultured in full serum (Fig. 1 B). Note that
under the latter conditions, Tyr phosphorylation of EGFR, ErbB2,
and ErbB4 receptors was markedly down-regulated by decorin in
full agreement with our previous studies (Santra et al., 2000; Zhu
et al., 2005), thereby validating our approach.
Next, we performed dose-response and time course experi
ments to investigate the effects of decorin on Met phosphorylation kinetics. We used a phosphoantibody specific for the two
Tyr residues located within the Met catalytic domain, Tyr1234
and Tyr1235. Decorin treatment of serum-starved cells evoked
a transient phosphorylation of these residues (Fig. 1 C, top).
In several experiments, we found a significant peak in phosphorylation at 10 min followed by pronounced down-regulation
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(Fig. 1 C, bottom). Interestingly, decorin induced a marked
decrease in steady-state levels of Met, as detected by immuno
blotting (Fig. 1 C, top). It is important to note that Met kinase
activity was required for decorin-evoked down-regulation of Met,
as tested by using SU11274, a specific Met tyrosine kinase inhibitor (Berthou et al., 2004; unpublished data). Remarkably, the
levels of total Met receptor declined very rapidly with a t1/2 of
6 min (Fig. 1 D) and partially recovered at 60 min after treatment. However, even after 24 h of continuous decorin treatment,
the Met levels were only 50% of control values (unpublished
data). The kinetics of decorin-evoked Met phosphorylation were
similar to those published for HGF in HeLa cells (Hammond
et al., 2003), with a peak between 5 and 10 min of stimulation.
In contrast, the kinetics of total Met degradation induced by HGF
were much slower than those of decorin, showing a comparable
down-regulation only after a 60-min treatment (Hammond et al.,
2003), although those experiments were performed in full
serum. These data suggest a role for decorin as a partial agonist
insofar as it activates the Met kinase domain but with an outcome different from that evoked by HGF.
Decorin binds directly to the Met receptor:
functional and biochemical evidence

We have previously shown that decorin binds directly to the
EGFR, initiating a cohort of cellular responses (Iozzo et al.,
1999b). Receptor cross talk is prevalent in cancer progression, and
Met and EGFR are no exception, with many studies showing a
link between the two either through direct interaction or by convergence of downstream signaling (Jo et al., 2000; Birchmeier et al.,
2003; Li et al., 2008a; Reznik et al., 2008). To assess whether the
observed effects on Met could be indirectly attributed to decorin/
EGFR binding, we used two different EGFR-blocking strate
gies: either the blocking monoclonal antibody mAb425 (Rodeck
et al., 1987) or AG1478, a specific EGFR tyrosine kinase inhibitor
(Levitzki and Gazit, 1995). Preincubation for 1 h with mAb425
was sufficient to abrogate EGFR activation as demonstrated by a
complete lack of phosphorylation in response to EGF (Fig. 2 A).
Blocking EGFR kinase activity with AG1478 gave similar results
(unpublished data). Even in the absence of EGFR activity, decorin
evoked a rapid activation of the Met catalytic domain (Fig. 2 B)
with no change in overall kinetics and a concurrent down-regulation
of total Met. We conclude that Met receptor activation by decorin
is independent of the EGFR.
This observation led us to hypothesize that decorin may
act through a direct interaction with the Met receptor. To explore this possibility, we used a noncleavable impermeable
cross-linker, S-SMPB (sulfo-succinimidyl-4-(p-maleimidophenyl)butyrate). After cross-linking, the Met receptor was immuno
precipitated with an antibody specific for the intracellular
C-terminal domain, and immunoblotting was performed to detect Met and decorin. We found that decorin protein core co
immunoprecipitated with Met in a complex of 190 kD (Fig. 2 C,
arrows). The size of the complex suggests a 1:1 stoichiometry
between decorin protein core (50 kD) and the  chain of the
receptor (140 kD; Fig. 2 C, asterisk).
Next, the physical interaction of decorin with Met was established in pull-down experiments using protein A–linked Sepharose

Figure 1. Decorin affects Met receptor signaling and turnover. (A) Phospho-RTK arrays. HeLa
cells were treated with decorin for 15 min. RTK
membranes were incubated with cell lysates.
The duplicate dots at each corner represent
phospho-Tyr positive controls. (B) The same
experiment as in A using nonquiescent cells.
(C, top) Representative immunoblot of a short
decorin time course showing phosphorylation
of the Met receptor at Tyr1234/5, total Met,
and -actin. (bottom) Quantification of immuno
blots similar to those shown in the top from
three independent experiments performed in
triplicate. Values represent the mean ± SEM
(**, P < 0.01). (D) Best-fit plot of Met receptor
degradation over time. Relative values were
obtained by scanning densitometry (chemiluminescence) of blots as in C and represent
means ± SEM from three independent experiments performed in triplicate.

beads, which efficiently bound a Met-Fc chimera comprised of the
extracellular domain of the Met fused to the Fc region of human
IgG (Fig. 2 D). By this approach, we were able to efficiently pull
down both HGF (Fig. 2 E) and decorin protein core (Fig. 2 F).
Some decorin bound nonspecifically to the beads, but the presence
of Met-Fc led to a significant enrichment in decorin binding.
Next, we determined the binding affinity of decorin to
immobilized Met-Fc chimera using solid-phase assays. Both
decorin and decorin protein core bound to Met-Fc in a saturable manner (Fig. 3, A and B) with Kd of 2.2 nM and 1.5 nM,
respectively. The biological activity of decorin and decorin protein core was tested by using fibrillar collagen type I, a known ligand for decorin. In this case, decorin and decorin core bound in
a saturable manner with Kd of 0.25 nM and 0.28 nM, respectively
(Fig. 3, C and D). In our assay, the binding of HGF alone to MetFc showed a Kd of 0.95 nM ± 0.47 (Fig. S1 A). As a negative control, we used a mouse monoclonal antibody as immobilized
substrate, and no significant binding to decorin was observed
(Fig. S1 B), ruling out the possibility that decorin binds non
specifically to the Fc portion of the Met-Fc chimera. In addition,
LG3 (the C-terminal portion of perlecan; Iozzo, 2005) did not
interact with Met-Fc (Fig. S1 C). This rules out a role for the
His tag in the binding insofar as LG3 has a His tag as decorin, it

is a protein of similar size to decorin, and is expressed in the same
eukaryotic cell system (293-EBNA cells).
Two ligands of Met have been previously identified: the
mammalian HGF and a bacterial leucine-rich repeat surface
protein called internalin B. HGF plays key roles in promoting
epithelial cell motility, growth, and differentiation (Birchmeier
et al., 2003). Internalin B activates Met, leading to internalization of the bacterial pathogen Listeria monocytogenes into host
cells (Shen et al., 2000; Ireton, 2007; Disson et al., 2008).
Recent structural studies have shown that internalin B binds to the
first Ig-like domain of Met (Niemann et al., 2007; Niemann et al.,
2008). In contrast, HGF binds with high affinity to the Met terminal Ig3-4 (Basilico et al., 2008) and with lower affinity to the
semaphorin domain (Stamos et al., 2004). To determine whether
decorin binds to regions within the Met ectodomain that overlap
with those used by HGF or internalin B, we performed competitive binding assays. First, we found that internalin B bound with
high affinity (Kd = 2.16 nM) to Met-Fc (Fig. 3 E). Note that the
Kd for Met/internalin B was previously reported to be 20–30 nM
(Machner et al., 2003). A possible explanation for this discrepancy in the observed affinity could be that the Met-Fc used in
our study is a dimer and fully glycosylated, whereas the Met
used in the referenced study was a monomer and produced in
DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
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Figure 2. Decorin interacts with the Met receptor. (A) 1 µg/ml mAb425, an EGFR-specific
blocking antibody, was tested before experiments in combination with decorin by evalua
ting its effect in inhibiting EGF-dependent
(16 nM) EGFR phosphorylation. (B, top)
Immunoblot of a short decorin (100 nM) time
course showing phosphorylation of the Met receptor at Tyr1234/5, total Met, and -actin in
the presence or absence of 1 µg/ml mAb425.
(bottom) Quantification of immunoblots similar
to those shown in the top panel. Values represent the mean ± SEM from three independent
experiments performed in triplicate (*, P <
0.05; **, P < 0.01). (C) Immunoblots detecting Met (left) and decorin (right) in cells treated
with decorin protein core for 15 min, crosslinked with 500 nM S-SMPB for 20 min at
37°C, and immunoprecipitated with an anti–C
terminus Met antibody. Arrows point to a high
Mr complex of Met and decorin protein core
(190 kD). The asterisk indicates Met monomer (140 kD). (D) Silver-stained gel. Notice
that the entire Met-Fc is bound to the protein
A–Sepharose beads. Smear is the carrier pro
teins. (E) Immunoblotting (IB) of HGF after pulldown with protein A beads–Met-Fc. (F) Immuno
blotting of decorin after pull-down with either
protein A beads–Met-Fc or beads alone. Note
the absence of HGF or decorin in the supernatants, indicating that essentially all of the
ligands were bound. IP, immunoprecipitation.
(D–F) Values shown are given in kiloDaltons.

glycosylation-deficient cells. HGF very effectively (50% inhibitory
concentration [IC50] = 2.3 nM) competed with decorin protein
core binding to Met-Fc (Fig. 3 F). In comparison, internalin B was
52-fold less efficient (IC50 = 120 nM) than HGF (Fig. 3 F).
Because the overall affinity constants for decorin, internalin B, and
HGF are relatively close (0.95–2.16 nM) in our assays, the conclusions from the competition experiments can be assessed as differential binding sites on the Met ectodomain for these ligands.
Collectively, our results demonstrate that decorin is a high
affinity ligand of the Met receptor insofar as it shows saturable kinetics of binding and displacement by two established Met ligands.
Moreover, the more efficient displacement by HGF suggests that
decorin and HGF bind to overlapping sites on the Met ectodomain
and further suggests that the decorin’s antagonistic effects might be
the result of a unique mode of binding within the Met receptor.
Decorin evokes differential tyrosine
phosphorylation of the Met receptor

In response to decorin binding, the kinase domain of Met is phosphorylated (Fig. 1 C and Fig. 2 B). In addition to Tyr1234/5,
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several other Tyr residues in the cytoplasmic tail of the Met receptor are known to undergo agonist-induced phosphorylation and
play key roles in downstream signaling (Fig. 4 A; Birchmeier et al.,
2003). For example, phosphorylation of Tyr1349 and Tyr1356 recruit the adaptor proteins Gab1 and Grb2, respectively, which are
responsible for mediating most of the complex cellular responses
(motility, growth, and differentiation; Birchmeier et al., 2003).
Conversely, phosphorylation of Tyr1003 is involved in negative
regulation of the receptor via recruitment of the E3 ubiquitin ligase
c-Cbl, which is responsible for Met polyubiquitination and subsequent degradation in the proteasome (Petrelli et al., 2002).
Decorin promoted phosphorylation of Tyr1003 (Fig. 4 B,
top), which was slightly delayed in comparison to HGF, with a
peak at 15 min (Fig. 4 B, bottom). Like the phosphorylation of resi
dues 1234/1235 (Fig. 1 C and Fig. 2 B), phosphorylation of
Tyr1003 in response to decorin was transient, with levels diminishing thereafter (not depicted). In support of this result, c-Cbl was recruited to the Met receptor after decorin treatment (Fig. 4 C).
Interestingly, the C-terminal Tyr1349 failed to be activated
in response to decorin, whereas cells robustly responded to

Figure 3. Affinity interaction between decorin and the Met receptor. (A–E) Ligand-binding assays using decorin, decorin protein core, or internalin B
as soluble ligands and Met-Fc or fibrillar collagen I as immobilized substrates. (F) Competition experiments using constant amounts of decorin core (10 nM)
and increasing amounts of internalin B or HGF as indicated. Notice that only at high molar ratios (20:1 and 40:1), internalin B significantly (70%)
reduces decorin protein core binding to the Met (IC50 = 180 nM). In contrast, HGF is much more efficient (IC50 = 2.5 nM) in displacing decorin core.
Values represent the mean ± SEM.

HGF (Fig. 4 D). This finding was unexpected, given that decorin
induces efficient activation of Met, as assessed by phosphorylation of the catalytic Tyr1234/5 (Fig. 1 C and Fig. 2 B). Moreover,
decorin induced robust recruitment of Grb2 to the Met receptor
(Fig. 4 E). Because phosphorylated Tyr1356 serves as docking
site for Grb2, this finding strongly suggests that decorin induces
efficient phosphorylation of this Tyr residue. Notably, Tyr1356
is essential for receptor internalization, and Grb2 also indirectly
recruits c-Cbl, leading to Met degradation (Li et al., 2007). Unfortunately, we were unable to directly assess phosphorylation
of Tyr1356 because of the fact that phospho-specific antibodies
recognizing this residue are not commercially available.
Collectively, our results show that decorin differentially
affects key Tyr residues involved in Met signaling and homeo
stasis, inducing efficient phosphorylation of Tyr1356 and Tyr1003
while inhibiting phosphorylation of Tyr1349, the sole Tyr associated with downstream signaling events. Decorin and HGF activate the receptor in subtly different ways, perhaps by inducing
different receptor conformations. This ability may be responsible
for the more efficient down-regulation of Met caused by decorin
(Fig. 4, B and D, top) and the lack of downstream signaling
(Fig. 4 D, bottom).
Decorin causes Met down-regulation
by inducing both ectodomain shedding
and internalization

It is known that Met can be down-regulated not only via Cblmediated ubiquitination and degradation in the proteasome, but

also by shedding of its ectodomain (Nath et al., 2001; Athauda
et al., 2006; Petrelli et al., 2006). Specifically, the shedding is
induced by a monoclonal Met-blocking antibody (Petrelli et al.,
2006), which is effective in inhibiting primary tumor growth
and metastastic spreading. Thus, we tested whether decorin
could use a similar mechanism of action. Media conditioned by
cells treated with decorin contained higher levels of shed Met
ectodomain than controls (Fig. S2 A).
It has been reported that the Met ectodomain can be released from the plasma membrane through activation of the
EGFR, a process that is mediated by a TIMP-3–sensitive pathway
(Nath et al., 2001). Accordingly, we tested TIMP-2 and TIMP-3
ability to prevent decorin-dependent Met down-regulation. Both
matrix metalloproteinase inhibitors were effective in blocking
decorin activity on the Met receptor (Fig. S2 B, top). We observed
that the full-length Met levels in cells incubated with the inhibitors were slightly higher than in control cells (Fig. S2 B, bottom).
This suggests the existence of a basal level of receptor shedding,
which is inhibited by TIMP-2 and TIMP-3. To test this possibility, we determined the amount of Met receptor shed into the
media conditioned by cells treated with decorin in the presence or
absence of the inhibitors. The results showed that both TIMP-2
and TIMP-3 reduced the amount of Met shedding (Fig. S2 C).
Note that the control medium (Fig. S2 C) was conditioned for
24 h, showing a significant level of basal Met shedding (compare
with Fig. S2 A).
To verify the contribution of Met internalization to Met
down-regulation upon decorin binding, HeLa cells were treated for
DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
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Figure 4. Decorin induces differential and selective phosphorylation of Met Tyr residues. (A) Diagram of the main Met
receptor Tyr phosphorylation sites and adaptor proteins. CAS,
Crk-associated substrate; P, phosphate. (B, top) Representative immunoblots of a short decorin (100 nM) time course
showing phosphorylation of the Met receptor at Tyr1003 and
total Met amount vis à vis 1.5 nM HGF. (bottom) Quantification of immunoblots from three independent experiments.
(C) Coimmunoprecipitation of c-Cbl and Met using an antibody directed toward the intracellular domain of Met. 100 nM
decorin treatment was performed for 10 min. (D, top) Representative immunoblot showing phosphorylation of the Met
receptor at Tyr1349 and total Met after 100 nM decorin
treatment vis à vis 1.5 nM HGF. (bottom) Quantification of
immunoblots from three independent experiments performed
in triplicate. (E) Recruitment of Grb2 to the Met receptor mediated by 100 nM decorin. Coimmunoprecipitation of the Met
receptor and Grb2 using an anti-Met C terminus antibody for
the immunoprecipitation (IP) and either the same antibody
or an anti-Grb2 monoclonal antibody for the immunoblotting
(IB). Values represent the mean ± SEM (*, P < 0.05; **, P <
0.01; ***, P < 0.001). All of the relative values were
obtained by scanning densitometry (chemiluminescence).
(B–E) Values shown are given in kiloDaltons.

5 and 30 min, subjected to immunostaining with a Met N terminus
antibody, and analyzed by fluorescence microscopy (Fig. S2 D).
Over time, decorin induced receptor relocation from the plasma
membrane to intracellular compartments and perinuclear regions.
This evidence was corroborated by biochemical data showing the
presence of Met upon decorin treatment followed by trypsin digestion (Fig. S2 E). This assay is based on the fact that only internalized Met is not accessible to digestion. Collectively, our results
provide a novel mechanism of action for decorin: inhibition of the
Met receptor biological activity via a dual activity comprising enhanced shedding and intracellular degradation.
Decorin down-regulates -catenin and
induces apoptosis via the Met receptor

Next, we investigated whether decorin-evoked Met downregulation could impair the -catenin pathway, a known downstream effector of Met (Monga et al., 2002; Herynk et al.,
2003; Rasola et al., 2007). After decorin treatment, -catenin
levels declined by 70% and 90% after 6 h and 24 h, respectively (Fig. 5 A). This degradation occurred via the proteasome,
the main degradation pathway for -catenin (Aberle et al., 1997),
insofar as it was completely blocked by the proteasome inhibitor
lactacystin (Fig. 5 B).
Next, we preincubated the cells with AG1478 and SU11274,
EGFR and Met-specific tyrosine kinase inhibitors (Levitzki and
Gazit, 1995; Berthou et al., 2004), respectively, in the presence or
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absence of decorin. AG1478 was not capable of inhibiting decorin
effect on -catenin levels, whereas SU11274 blocked decorinevoked -catenin degradation (Fig. 5 C). Importantly, the effect of
decorin on the -catenin pathway was direct and not the result of
induction of apoptosis as proven by lack of poly ADP-ribose polymerase (PARP) cleavage after 6-h treatment (Fig. 5 C, top). In
agreement with the biochemical data, the total levels of -catenin
were markedly reduced by decorin treatment as detected by qualitative and quantitative fluorescence microscopy (Fig. 6, A, C, and E).
Notably, there was a marked displacement of -catenin from perinuclear to plasmalemmal regions (Fig. 6, B and D). Finally, we
tested whether decorin could cause -catenin degradation in the
presence or absence of LiCl, a known inhibitor of GSK3 (Klein
and Melton, 1996). The results clearly showed that LiCl potently
stabilized -catenin levels in the absence of decorin but was not
capable of inhibiting decorin-evoked -catenin down-regulation
(Fig. 6 F). These findings were corroborated by functional tests
assessing -catenin transcriptional activity. We performed
transient cell transfection assays using the TopFlash reporter vector, which drives the expression of a luciferase reporter gene under
the control of a T cell factor promoter, which is activated by endog
enous -catenin. Decorin significantly inhibited -catenin activity
in the presence or absence of LiCl (Fig. 6 G). The persistence of
decorin activity in the presence of LiCl suggests that decorin
evokes down-regulation of -catenin independently of the canonical Wnt pathway, which requires GSK3.

Figure 5. Decorin down-regulates -catenin via the Met receptor. (A, top) Representative immunoblots of HeLa cells treated with 100 nM decorin for the
times indicated and probed for -catenin. Tubulin was used as a loading control. (bottom) Quantification of immunoblots as those presented in the top panel
from three independent experiments. (B, top) -Catenin levels after treatment with 100 nM decorin for 30 min in the presence or absence of 10 µM of the
proteasome inhibitor lactacystin. Cells were preincubated with lactacystin for 1 h before adding decorin. (bottom) Quantification of immunoblots as those
presented in the top panel from three independent experiments. (C, top) -Catenin and PARP immunoblots after treatment with 100 nM decorin for 6 h in
the presence or absence of the tyrosine kinase inhibitors AG1478 and SU11274 (both 1 µM) as indicated. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as loading control. (bottom) Quantification of immunoblots as those presented in the top panel from three independent experiments
performed in triplicate. Values represent the mean ± SEM (*, P < 0.05; **, P < 0.01). All of the relative values were obtained by scanning densitometry
(chemiluminescence). Values shown in blots are given in kiloDaltons.

Next, on the basis of our previous studies showing that
decorin induces apoptosis of A431 (Seidler et al., 2006) and
MTLn3 (Goldoni et al., 2008) cells, we tested whether the same
would happen in HeLa cells and whether the Met receptor
could be linked to decorin-evoked apoptosis. Decorin treatment
stimulated significant PARP cleavage after 24 h, and this effect
was blocked by SU11274 (Fig. S3 A). Moreover, decorin induced caspase-3/7 activity comparable with the levels induced
by etoposide, an inhibitor of the topoisomerase II enzyme, and
it did so in a Met-dependent manner (Fig. S3 B). VAD, a pancaspase inhibitor, was used to block decorin’s activity, and its
effects can be compared to those evoked by the Met kinase inhibitor SU11274. These results suggest that Met phosphorylation is required for decorin-evoked apoptosis and reinforce our
evidence that the Met receptor is a key player in decorin’s
mechanism of action.
Decorin inhibits cell motility by a
mechanism that involves both Met
and EGFR

Deregulation of the Met receptor has been linked to the invasive
behavior of tumor cells (Birchmeier et al., 2003). We have recently shown that decorin can prevent metastastic spreading to
the lungs in a breast cancer model (Goldoni et al., 2008). In this
study, we add an in vitro functional assay to support the relevance of our findings. HeLa cells were grown to confluency,
“scratched” to allow motility, and treated with decorin for 24 h

in the presence or absence of AG1478, H9786, a Met-blocking
antibody, or the combination of both. Decorin significantly inhibited cell migration compared with control cells (Fig. S4).
Both AG1478 and H9786, used alone, were effective but to a
lesser extent than decorin. Interestingly, when decorin was used
in combination with either inhibitor, it prevented wound closure
even further than the individual compounds. When decorin was
added in the presence of both inhibitors, it did not have any
additional effect (Fig. S4, bottom). These data support the idea
that both Met and EGFR are important to sustain cell migration
and that decorin inhibits in vitro cell motility by a dual action on
both receptors. Note that decorin is capable of down-regulating
the Met receptor also in full-serum medium (Fig. S3 C), supporting the biological data regarding inhibition of the -catenin
pathway and cell migration, both performed in the presence of
serum. In addition, once decorin is removed from the cells, Met
expression is recovered over time, indicating that the cells are
healthy and apoptosis is not occurring.

Discussion
The multifaceted ability of decorin to retard in vivo tumor growth
and metastatic spreading has a mechanistic explanation in decorin’s ability to down-regulate multiple signaling pathways. We
show for the first time that decorin is a novel endogenous antagonistic ligand of the Met receptor. Signaling mediated by HGF/Met
axis promotes multiple biological activities, including survival,
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Figure 6. Decorin attenuates -catenin levels and transcriptional activity. (A–D) Representative -catenin immunofluorescence images of HeLa cells after
a 2-h incubation with or without 100 nM decorin. Notice the marked decline in -catenin levels throughout the cytoplasm and perinuclear regions in the
decorin-treated cells. In contrast, the plasma membrane localization of -catenin increases (D, arrows). Nu, nucleus. Bars: (A and C) 50 µm; (B and D) 10 µm.
(E) Quantification of the fluorescence intensity of images similar to those shown in A and C. The values represent the mean ± SEM of 12 images (120
cells/image) from four independent experiments. (F) Decorin inhibits -catenin activity via a GSK3-–independent mechanism. Representative -catenin
immunoblot of HeLa lysates treated with 100 nM decorin for 6 h in the presence or absence of 30 mM of the GSK3- inhibitor LiCl. Cells were preincubated
with LiCl for 1 h in full serum before decorin treatment. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (G) HeLa
cells were cotransfected with the TopFlash vector and a vector carrying the R. reniformis luciferase. 12 h after transfection, cells were treated with or without
100 nM decorin or LiCl for 6 h. Luciferase activity was measured after incubation with the cognate substrate luciferin. The values were normalized on
R. reniformis luciferase activity. Cells preincubated with 30 mM LiCl, as in F, showed the same degree of reduction in luciferase activity when treated with
decorin. Notice that LiCl enhances -catenin activity (***, P < 0.001). The values represent the mean ± SEM of five independent experiments performed
in triplicate. TCF, T cell factor.

proliferation, motility/invasion, and angiogenesis (Trusolino and
Comoglio, 2002; Birchmeier et al., 2003). Deregulation of the Met
signaling pathway leads to uncontrolled growth and transformation, as shown by the TPR-Met, an oncogene that exhibits constitutive tyrosine kinase activation, and by activating mutations of Met
intracellular domain in both hereditary and sporadic cancers
(Gentile et al., 2008). Our results indicate that decorin is an inhibitor of multiple RTKs, insofar as it down-regulates the Met receptor
as well as ErbB family members. The unique activity of decorin as
a Met antagonist is manifested by a rapid induction of both Met receptor shedding and internalization with consequent downstream
degradation of -catenin, which is required for cell survival.
To date, there is only one known mammalian ligand of the
Met receptor (i.e., HGF) and one bacterial protein, internalin B,
which is synthesized and partly secreted by Lysteria monocytogenes. Internalin B, a protein containing seven leucine-rich tandem
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repeats with homology to decorin, mimics HGF-induced receptor
trafficking (Li et al., 2005) and causes sustained activation of the
Met receptor (Shen et al., 2000), leading to bacterial internalization
into host cells (Shen et al., 2000; Ireton, 2007; Disson et al., 2008).
The 213–amino acid leucine-rich repeat portion of internalin B is
sufficient for entry into mammalian cells (Braun et al., 1999). The
recent cocrystallization of internalin B with the ectodomain of the
Met receptor has shown that internalin B complexes with the first
Ig domain of the receptor (Niemann et al., 2007; Niemann et al.,
2008). This interaction keeps Met in an active configuration while
maintaining the flexibility in the Met semaphorin domain, where
HGF binds with low affinity (Stamos et al., 2004). The interaction
interface includes the concave part of the leucine-rich domain of
internalin B and a loop that protrudes from the first Ig-like domain
of the Met receptor (Niemann et al., 2008). Notably, several key
aromatic amino acids within the concave face of internalin B are

required for Met binding and internalization of the bacteria
(Machner et al., 2003). These results have been confirmed in the
aforementioned cocrystallization study (Niemann et al., 2007).
Mutation of each of these residues (Fig. S5 A) abolishes binding
to the Met receptor (Machner et al., 2003). Very importantly, a
specific sequence of internalin B, encoding Y170 (required for
Met binding) and surrounding residues, is highly analogous to a
sequence of mammalian decorin (Fig. S5 B). This highly conserved motif suggests that both proteins have evolved to fulfill a
common function, i.e., interacting with the Met receptor, albeit
with divergent outcomes.
In contrast to internalin B, HGF binds with low affinity to
the Met semaphorin domain (Stamos et al., 2004) and with high
affinity to the terminal Ig3-4 (Basilico et al., 2008). This is in
agreement with early biochemical experiments demonstrating
that internalin B and HGF do not substantially compete for receptor occupancy (Shen et al., 2000). We discovered that decorin
is readily displaced by HGF (IC50 = 2.3 nM) from binding to
the immobilized Met ectodomain fused to the dimerizing Fc
fragment. In contrast, internalin B was much less efficient in displacing decorin binding to Met-Fc because it required >50-fold
higher concentrations (IC50 = 120 nM). These findings suggest
that decorin binds to a similar location of the Met ectodomain
where HGF binds with additional secondary sites overlapping
with internalin B binding.
In spite of the fact that decorin mode of binding to the Met
ectodomain is apparently similar to that of HGF, decorin evokes a
profound antagonistic effect on the receptor signaling by inducing
both physical and functional receptor down-regulation and by
triggering apoptosis via induction of caspase-3/7 activity. Moreover, decorin causes Met-mediated down-regulation of -catenin
levels and transcriptional activity. It is well established that the
Met receptor not only physically interacts with -catenin on the
cell surface but upon HGF binding, also phosphorylates -catenin
and triggers its translocation into the nucleus and consequent
transcription of genes vital for cell proliferation and migration
(Monga et al., 2002; Müller et al., 2002; Herynk et al., 2003;
Ishibe et al., 2006; Rasola et al., 2007). Importantly, the Met receptor and -catenin are engaged in a positive feedback loop that
sustains tumor growth and invasion, where -catenin drives Met
receptor expression (Rasola et al., 2007). -Catenin is a key player
in Wnt signaling and plays a central role in cancer development
(Clevers, 2006). For instance, -catenin regulates both differentiation and proliferation of intestinal epithelial cells by enhancing
the expression of genes, such as cyclin D1 and D4, associated
with tumor progression. The ability of exogenous decorin to suppress -catenin levels and transcriptional activity, coupled with
the decorin-evoked translocation of -catenin from the peri
nuclear to plasmalemmal compartments, suggests that decorin
signaling affects the -catenin pathway. Our data show that this
effect is mediated through the Met pathway. A recent study using
decorin-deficient mice has shown that 30% of these mutant
mice develop intestinal tumors, a process that is accelerated and
amplified when the decorin-deficient animals are subjected to a
high risk diet (Bi et al., 2008). Notably, the endogenous -catenin
levels were markedly increased in the intestinal epithelium of the
decorin-null mice, suggesting that lack of decorin is permissive

for tumorigenesis, as we hypothesized previously (Iozzo et al.,
1999a), thereby providing in vivo evidence that -catenin might
be regulated by extracellular signaling events evoked by decorin.
How does decorin induce protracted Met degradation? In
the case of the EGFR, EGF but not TGF- induces efficient receptor internalization and degradation. EGF remains closely linked
to its receptor during clathrin-dependent endocytosis, whereas
TGF- rapidly dissociates from the receptor in the acidic microenvironment of early endosomes, resulting in receptor recycling
(Schlessinger, 2000). Decorin causes a caveolar-mediated endocytosis of the EGFR, and even after 30 min, decorin and EGFR
colocalize within late endocytic compartments and subsequently
within lysosomes (Zhu et al., 2005). This mechanism might explain the lower levels of EGFR after decorin treatment due in part
to a reduced receptor recycling to the surface. A similar scenario
could occur with the Met receptor, although we have not formally
shown that Met internalization and degradation occur via a
caveolar-mediated endocytosis. This idea is supported by a recent
study, which has shown that both internalin B and the leucine-rich
repeats of internalin B, the region that shares analogy with decorin,
are properly internalized and remain associated with Met during
transit through early and late endosomes when provided as soluble
ligands to HeLa cells (Gao et al., 2009). Thus, one possibility is
that HGF/internalin B, as agonistic ligands for Met, are internalized via a clathrin-mediated pathway and in analogy with EGF/
EGFR, clathrin-mediated internalization has been shown to be essential for sustained receptor signaling (Sigismund et al., 2008).
In contrast, antagonistic ligands such as decorin could induce internalization via a caveolar-mediated pathway, leading to attenuated signaling and intracellular proteolysis of the receptor.
The ability of decorin to differentially phosphorylate Met
receptor Tyr residues is fascinating. More investigation into this
novel decorin mechanism of action will be needed in the future,
and most likely, more information regarding the peculiar Met
conformation induced by decorin binding will shed light onto the
phosphorylation events described in this study. Notably, coactivation of RTKs affects the response of tumor cells to targeted therapies (Stommel et al., 2007), and amplification of the Met-encoding
gene promotes drug resistance in ErbB-driven cancers (Engelman
et al., 2007). Although in the past main efforts were aimed at developing highly specific inhibitors acting on single RTKs, more
recently there has been a general consensus that molecules interfering simultaneously with multiple RTKs might be more effective than single target agents (Knudsen and Vande Woude, 2008).
In this perspective, the activity of decorin, and perhaps of other
molecules harboring leucine-rich repeats, might represent a novel
therapeutic modality against metastatic cancer.

Materials and methods
Cell culture and materials
HeLa cells were obtained from American Type Culture Collection and maintained in DME (Mediatech) supplemented with 10% FBS (PAA Laboratories,
Inc). Dulbecco’s phosphate buffer saline was purchased from Mediatech.
Cell culture supplies were purchased from Thermo Fisher Scientific. The following antibodies were used: monoclonal mouse anti-Grb2, anti–-catenin,
antiphosphotyrosine HRP conjugated (BD), anti–-actin (Sigma-Aldrich),
anti-PARP (BD), monoclonal rabbit against EGFR-Tyr1173, Met-Tyr1234/5, MetTyr1003, Met-Tyr1349 (Cell Signaling Technology), polyclonal against Met
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C terminus (Santa Cruz Biotechnology, Inc.), Met N terminus (H9786 [SigmaAldrich] and AF276 [R&D Systems]), and HGF (Abcam). Lactacystin was
purchased from Sigma-Aldrich. Anti–human decorin antibody (LC-001b)
was provided by LifeCell Corporation. EGFR-blocking antibody mAb425
was provided by U. Rodeck (Thomas Jefferson University, Philadelphia, PA).
The EGFR tyrosine kinase inhibitor, AG1478, was obtained from EMD.
HRP-conjugated donkey anti–rabbit and sheep anti–mouse were purchased
from Jackson ImmunoResearch Laboratories. Protein G– and A–Sepharose
beads were obtained from GE Healthcare. S-SMPB and SuperSignal West
Pico chemiluminescence substrate were purchased from Thermo Fisher Scientific. HGF, TIMP-2, and TIMP-3 were purchased from R&D Systems. Rat
tail collagen type I was obtained from BD. Human recombinant decorin
was expressed and purified as described previously (Zhu et al., 2005).
Decorin harbors one glycosaminoglycan side chain and is fully glycosylated. Decorin protein core was obtained by expressing a mutant at the
glycosaminoglycan chain attachment site. Decorin protein core is expressed
in a mammalian cell system and is fully glycosylated.
Phospho-RTK arrays, time course experiments, and blocking experiments
Arrays were purchased from R&D Systems. Array membranes were incubated with cell lysates and processed as recommended by the manufacturer’s protocol using a Phospho-Tyr–specific antibody. Approximately 8 × 106
HeLa cells were either serum starved or maintained in full serum overnight
and treated with 100 nM decorin for 15 min or left untreated. After decorin
incubation, cells were washed with ice-cold PBS and lysed with a buffer
containing 1% NP-40, 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM Na3VO4, 10 µg/ml aprotinin, and 10 µg/ml leupeptin for 30 min. Protein assay (Bio-Rad Laboratories) was performed
before incubating the lysates with the RTK membranes. HeLa cells were
serum starved overnight before treatment with 100 nM decorin for 5, 10,
15, 30, and 60 min. Cells were washed with ice-cold PBS and lysed in RIPA
buffer. 10 µg/ml EGFR-blocking antibody mAb425 or 1 µM AG1478 were
incubated with or without decorin. HGF was used at 1.5 nM. Lysates were
resolved on an 8% SDS-PAGE. Cells were preincubated with mAb425 or
AG1478 for 1 h before decorin treatment. Efficiency of mAb425 and
AG1478 was measured by testing their ability to block EGFR phosphorylation evoked by EGF (16 nM for 5 min).
Cross-linking and immunoprecipitation
Cells were treated with or without 220 nM decorin protein core for 15 min
and incubated with 0.5 mM of the noncleavable cross-linker S-SMPB for
20 min at 37°C (Zhu et al., 2005). At the end, reactions were quenched
with a 90-mM glycine solution. Cells were washed with ice-cold PBS and
lysed with an NP-40–containing buffer (as described in Phospho-RTK arrays, time course…). Cell extracts were subjected to immunoprecipitation
with an anti–C terminus Met receptor antibody, separated on a 6% SDSPAGE, and immunoblottings for Met and decorin were performed. Met
was also immunoprecipitated to examine c-Cbl and Grb2 recruitment to
the receptor before and after decorin treatment. Approximately 3 × 106
HeLa cells were serum starved overnight for this purpose.
Pull-down– and solid-phase–binding assays
Human Met-Fc chimera (Sigma-Aldrich) was bound to protein A–Sepharose
beads (GE Healthcare). 2 µg human Met/Fc chimera was added to 20 µl
protein A–Sepharose beads. After an overnight incubation with rotation at
4°C, the beads were extensively washed with PBS and resuspended in 400 µl
of serum-free medium containing Complete Mini protease inhibitor (Roche).
The mixture was incubated with equimolar amounts of various ligands at
37°C for 3 h. The beads were collected by centrifugation, extensively washed
with a buffer containing 0.1% Triton X-100, boiled in reducing sample buffer,
and subjected to electrophoresis on an 8% SDS-PAGE. In these experiments,
antibodies against human HGF (Abcam) and decorin (Santa Cruz Biotechnology, Inc.) were used. ELISAs were performed following a standard protocol. The substrates, either Met-Fc (100 ng/well) or neutralized fibrillar
collagen type I (1 mg/ml; 50 µl/well), were allowed to adhere to the wells
(BD) overnight at room temperature in the presence of carbonate buffer, pH
9.6. Plates were washed with PBS and incubated for 3 h with serial dilutions
of decorin or decorin core. In the competition experiments, decorin core was
kept at constant concentration (10 nM) and incubated with increasing concentrations of either internalin B or HGF. After ligand incubation, plates were
extensively washed with PBS, blocked with 1% BSA solution in PBS, and incubated with primary and HRP-conjugated secondary antibodies. Signal
was developed using Sigma-Fast tablets (Sigma-Aldrich) and read at 450-nm
OD. To correct for antibody affinity, the values obtained were converted to
bound ligand (nanomolars) by performing separate ELISA experiments using
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increasing amounts of each ligand and extrapolating from the generated
standard curves.
Ectodomain shedding and slot blot
HeLa cells were serum starved overnight and treated with 100 nM decorin
for 5–30 min. Conditioned media from decorin-treated cells and controls
were collected, slot blotted, and probed for the N-terminal domain of the
Met receptor. For the inhibition of shedding experiments, 1 µM TIMP-2 and
TIMP-3 were incubated for 30 min before decorin treatment (100 nM for
30 min). Both lysates and media were collected and analyzed by Western
analysis and slot blot, respectively. Lysates were probed with a Met antibody recognizing the intracellular domain of the receptor, whereas media
with an antibody raised against the Met extracellular domain.
Met internalization experiments
Cells for immunofluorescence were grown on chamber glass slides, treated
with decorin, washed with PBS, fixed in ice-cold methanol for 5 min, and
stained according to standard procedures. To detect Met, the AF276 antibody (R&D Systems) raised against the N terminus domain of the receptor
was used followed by an FITC-conjugated donkey anti–goat antibody
(Santa Cruz Biotechnology, Inc.). Images were acquired on a laser-scanning confocal microscopy system (LSM 510 META; Carl Zeiss Inc.) driven
by imaging software (LSM 510; Carl Zeiss, Inc.). 63× magnification was
used with a 1.25 objective lens aperture. Confocal image processing, including z stacks, was performed with ImageJ (National Institutes of Health).
Contrast enhancement was applied uniformly to all panels. A microscope
(BX51; Olympus) driven by SPOT Advanced imaging software (version
4.0.9; Diagnostic Instruments, Inc.) was used to acquire fluorescence
images with 40× magnification and 0.75 aperture. FITC signal was acquired
at 25°C. Vectashield mounting medium was purchased from Vector Laboratories. Approximately 8 × 106 HeLa cells were serum starved for 1 h before decorin treatment (100 nM for 5 and 30 min). Cells were trypsinized
with 0.2% trypsin (Cellgro) for 5 min at 37°C and pelleted by centrifugation at 300 g for 5 min. The pellet was dissolved in RIPA buffer, and samples were run on SDS-PAGE.
-Catenin experiments and migration assays
For the -catenin experiments, subconfluent HeLa cells in DME full serum
were used. Cells were treated with 100 nM decorin from 30 min to 24 h.
For the GSK3- inhibition experiments, cells were incubated with 30 mM
LiCl for 1 h before decorin treatment. Cells for immunofluorescence were
grown on chamber slides, treated with decorin, fixed in ice-cold methanol for
5 min, and stained according to standard procedures. To detect the -catenin
signal, a rhodamine-conjugated goat anti–mouse antibody was used (Santa
Cruz Biotechnology, Inc.). To study the effect of decorin on -catenin transcriptional activity, we used the TopFlash luciferase reporter vector (Addgene). TopFlash vector was provided by M. Pacifici (Thomas Jefferson
University, Philadelphia, PA). Subconfluent HeLa cells in 12-well plates were
transfected overnight with TopFlash and a Renilla reniformis luciferase reporter vector (phRL-TK; Promega) as transfection control in the ratio 10:1
(TopFlash:R. reniformis) using Lipofectamine2000 (Invitrogen). The next day,
media were changed and cells were treated with or without 30 mM LiCl for
1 h before decorin (100 nM) stimulation for 6 h. Cells were lysed, and the
luciferase activity was measured using a dual luciferase assay kit (Promega).
The FopFlash mutant was used vis à vis the TopFlash vector as negative control to evaluate the background signal. No luciferase activity was observed
with the FopFlash vector.
For migration assays, HeLa cells were grown to confluency in 12-well
plates and scratched with a pipette tip. Cells were incubated for 24 h with
or without 100 nM decorin, 1 µM AG1478, and 2 µg/ml Met-blocking anti
body H9786 in full serum. Blocking agents were incubated for 1 h before
decorin treatment. An inverted phase-contrast microscope (IM; Olympus)
with 10× magnification and 0.25 aperture was used. Pictures were taken
over time with a digital microscope camera (DP12; Olympus).
Quantification and statistical analysis
Immunoblots were quantified by scanning densitometry using Scion Image
software (National Institutes of Health). Graphs were generated using SigmaStat (version 3.10; Systat Software, Inc.). Significance of the differences was
evaluated by Student’s t test. Fluorescence intensity was quantified by measuring pixels with ImageJ software. In the scratch assay, wound closure was measured with ImageJ. The mean of three linear distances between the two edges
of the wound was measured. Three wounds per condition were analyzed.
Three independent experiments were run. All data presented were collected
from three independent experiments run in triplicates or quadruplicates.

Online supplemental material
Fig. S1 shows a representative HGF/Met-Fc solid-phase binding curve and
negative controls for the binding experiments, decorin/IgG, and LG3/Met-Fc.
Fig. S2 shows decorin-induced Met ectodomain shedding and Met
internalization after decorin binding. Fig. S3 shows induction of apoptosis
downstream of decorin-evoked Met phosphorylation and down-regulation
of Met by decorin treatment in full serum followed by recovery of Met expression upon decorin withdrawal. Fig. S4 shows a motility assay. Fig. S5 presents the 3D structure of internalin B leucine-rich repeats and a key portion of
the sequence alignment with decorin. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200901129/DC1.
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